{"id":336609,"date":"2019-03-05T01:00:00","date_gmt":"2019-03-05T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/espoir-pour-les-patientes-atteintes-dun-cancer-du-sein-her2-positif-et-dune-maladie-residuelle-invasive\/"},"modified":"2019-03-05T01:00:00","modified_gmt":"2019-03-05T00:00:00","slug":"espoir-pour-les-patientes-atteintes-dun-cancer-du-sein-her2-positif-et-dune-maladie-residuelle-invasive","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/espoir-pour-les-patientes-atteintes-dun-cancer-du-sein-her2-positif-et-dune-maladie-residuelle-invasive\/","title":{"rendered":"Espoir pour les patientes atteintes d&#8217;un cancer du sein HER2-positif et d&#8217;une maladie r\u00e9siduelle invasive"},"content":{"rendered":"<p><strong>Si les patientes atteintes d&#8217;un cancer du sein HER2-positif ne parviennent pas \u00e0 obtenir une r\u00e9mission compl\u00e8te malgr\u00e9 l&#8217;\u00e9puisement des options th\u00e9rapeutiques courantes, le risque de r\u00e9cidive est \u00e9lev\u00e9. Les r\u00e9sultats d&#8217;une \u00e9tude ouverte de phase III sur le trastuzumab emtansine suscitent l&#8217;espoir.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>L&#8217;\u00e9tude ouverte de phase III a port\u00e9 sur 1486 patientes atteintes d&#8217;un cancer du sein HER2-positif qui pr\u00e9sentaient une maladie r\u00e9siduelle invasive malgr\u00e9 une chimioth\u00e9rapie n\u00e9oadjuvante, ainsi qu&#8217;un traitement ciblant HER2 suivi d&#8217;une chirurgie. Randomis\u00e9es 1:1, elles ont re\u00e7u pendant 12 semaines 14 cycles du conjugu\u00e9 anticorps-m\u00e9dicament, compos\u00e9 de l&#8217;anticorps monoclonal anti-HER2 trastuzumab emtansine (T-DM1) li\u00e9 \u00e0 l&#8217;inhibiteur de microtubules DM1, ou du trastuzumab. La survie sans maladie invasive (IDFS) a \u00e9t\u00e9 d\u00e9finie comme crit\u00e8re d&#8217;\u00e9valuation principal.<\/p>\n<p>L&#8217;analyse des r\u00e9sultats a montr\u00e9 que T-DM1 am\u00e9liorait significativement l&#8217;IDFS par rapport au trastuzumab. Au total, 256 \u00e9v\u00e9nements IDFS ont \u00e9t\u00e9 enregistr\u00e9s, dont 91 (12,2%) dans le r\u00e9gime T-DM1 et 165 (22,2%) dans le groupe t\u00e9moin (ratio de risque non stratifi\u00e9 (HR) : 0,50 ; intervalle de confiance (IC) \u00e0 95% : 0,39-0,64 ; p&lt;0,0001). L&#8217;\u00e9valuation de la survie globale n&#8217;a pas encore \u00e9t\u00e9 effectu\u00e9e. Une phase de suivi plus longue devrait fournir des informations plus pr\u00e9cises \u00e0 ce sujet.<\/p>\n<p>\n<em>Source : Geyer Jr. CE, et al. : \u00c9tude de phase III du trastuzumab emtansine (T-DM1) vs trastuzumab en traitement adjuvant chez des patientes atteintes d&#8217;un cancer du sein pr\u00e9coce HER2-positif avec maladie invasive r\u00e9siduelle apr\u00e8s chimioth\u00e9rapie n\u00e9oadjuvante et traitement cibl\u00e9 sur HER2 incluant le trastuzumab : R\u00e9sultats primaires de KATHERINE. Abstract GS1_10, SABCS 2018<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>InFo ONKOLOGIE &amp; H\u00c9MATOLOGIE 2019 ; 7(1) : 32<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Si les patientes atteintes d&#8217;un cancer du sein HER2-positif ne parviennent pas \u00e0 obtenir une r\u00e9mission compl\u00e8te malgr\u00e9 l&#8217;\u00e9puisement des options th\u00e9rapeutiques courantes, le risque de r\u00e9cidive est \u00e9lev\u00e9. Les&hellip;<\/p>\n","protected":false},"author":7,"featured_media":87071,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Symposium sur le cancer du sein de San Antonio","footnotes":""},"category":[11527,11422,11389,11535,11549],"tags":[13591,13596],"powerkit_post_featured":[],"class_list":["post-336609","post","type-post","status-publish","format-standard","has-post-thumbnail","category-etudes","category-gynecologie","category-oncologie","category-rapports-de-congres","category-rx-fr","tag-cancer-du-sein","tag-cancer-du-sein-fr","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-15 15:40:52","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":336611,"slug":"speranza-per-le-pazienti-con-tumore-al-seno-her2-positivo-e-malattia-invasiva-residua","post_title":"Speranza per le pazienti con tumore al seno HER2-positivo e malattia invasiva residua","href":"https:\/\/medizinonline.com\/it\/speranza-per-le-pazienti-con-tumore-al-seno-her2-positivo-e-malattia-invasiva-residua\/"},"pt_PT":{"locale":"pt_PT","id":336618,"slug":"esperanca-para-doentes-com-cancro-da-mama-her2-positivo-e-doenca-residual-invasiva","post_title":"Esperan\u00e7a para doentes com cancro da mama HER2-positivo e doen\u00e7a residual invasiva","href":"https:\/\/medizinonline.com\/pt-pt\/esperanca-para-doentes-com-cancro-da-mama-her2-positivo-e-doenca-residual-invasiva\/"},"es_ES":{"locale":"es_ES","id":336593,"slug":"esperanza-para-las-pacientes-con-cancer-de-mama-her2-positivo-y-enfermedad-invasiva-residual","post_title":"Esperanza para las pacientes con c\u00e1ncer de mama HER2-positivo y enfermedad invasiva residual","href":"https:\/\/medizinonline.com\/es\/esperanza-para-las-pacientes-con-cancer-de-mama-her2-positivo-y-enfermedad-invasiva-residual\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/336609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=336609"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/336609\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/87071"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=336609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=336609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=336609"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=336609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}